See more : Investec plc (INVR.L) Income Statement Analysis – Financial Results
Complete financial analysis of Dyadic International, Inc. (DYAI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Dyadic International, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Shalag Industries Ltd (SALG.TA) Income Statement Analysis – Financial Results
- Premier Foods plc (PRRFY) Income Statement Analysis – Financial Results
- PCCW Limited (PCCWY) Income Statement Analysis – Financial Results
- LY Corporation (4689.T) Income Statement Analysis – Financial Results
- Diamant Art Corp. (DIAAF) Income Statement Analysis – Financial Results
Dyadic International, Inc. (DYAI)
About Dyadic International, Inc.
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and collaboration with Syngene International Limited. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.90M | 2.93M | 2.40M | 1.60M | 1.68M | 1.30M | 758.42K | 592.89K | 315.71K | 12.52M | 17.13M | 15.60M | 15.38M | 15.88M | 16.74M | 211.27K |
| Cost of Revenue | 1.98M | 2.12M | 1.94M | 1.42M | 1.46M | 1.03M | 680.20K | 516.16K | 124.01K | 8.18M | 9.72M | 7.62M | 11.35M | 12.86M | 12.83M | 175.44K |
| Gross Profit | 922.96K | 807.11K | 459.39K | 176.99K | 221.38K | 268.17K | 78.22K | 76.72K | 191.70K | 4.35M | 7.41M | 7.99M | 4.04M | 3.03M | 3.91M | 35.83K |
| Gross Profit Ratio | 31.84% | 27.54% | 19.11% | 11.05% | 13.17% | 20.70% | 10.31% | 12.94% | 60.72% | 34.71% | 43.25% | 51.18% | 26.25% | 19.05% | 23.34% | 16.96% |
| Research & Development | 3.30M | 4.50M | 8.39M | 3.87M | 3.96M | 3.32M | 2.20M | 885.60K | 124.01K | 2.19M | 1.00M | 921.71K | 4.24M | 4.90M | 3.62M | 0.00 |
| General & Administrative | 5.82M | 6.42M | 6.70M | 6.08M | 5.52M | 4.52M | 5.03M | 4.56M | 3.84M | 6.11M | 4.99M | 4.48M | 7.15B | 5.32M | 3.76M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.24M | 944.12K | 700.78K | 3.42B | 2.81M | 1.86M | 0.00 |
| SG&A | 5.82M | 6.42M | 6.70M | 6.08M | 5.52M | 4.52M | 5.03M | 4.56M | 3.84M | 7.36M | 5.94M | 5.50M | 10.57M | 8.13M | 5.61M | 42.54K |
| Other Expenses | 38.42K | 250.00K | 6.09M | 187.39K | 2.30M | 2.04M | 220.72K | 436.92K | 0.00 | 0.00 | 0.00 | 0.00 | -28.70K | -16.79K | 0.00 | 184.07K |
| Operating Expenses | 9.15M | 10.92M | 15.09M | 10.14M | 9.48M | 7.84M | 7.45M | 5.88M | 3.84M | 9.55M | 6.94M | 5.87M | 14.77M | 13.01M | 9.24M | 226.61K |
| Cost & Expenses | 11.13M | 13.05M | 17.03M | 11.57M | 10.94M | 8.87M | 8.13M | 6.40M | 3.96M | 17.72M | 16.66M | 13.49M | 26.12M | 25.87M | 22.07M | 402.05K |
| Interest Income | 416.69K | 180.42K | 51.70K | 447.00K | 984.93K | 0.00 | 0.00 | 485.49K | 11.16K | 28.06K | 14.61K | 695.85K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 894.53K | 566.15K | 909.00 | 11.16K | 683.21K | 686.02K | 0.00 | 594.16K | 710.54K | 597.91K | 0.00 |
| Depreciation & Amortization | 0.00 | 10.12M | 3.49M | 9.96M | 9.25M | 7.40M | 7.38M | 5.81M | -2.17M | 271.13K | 253.50K | 256.48K | 250.18K | 602.73K | 586.69K | 0.00 |
| EBITDA | -8.23M | -10.07M | -13.07M | -10.19M | -9.23M | -7.55M | -2.20M | 0.00 | -5.82M | -5.45M | 726.69K | 1.82M | -9.91M | -9.13M | -4.87M | -190.78K |
| EBITDA Ratio | -283.90% | -343.51% | -671.40% | -635.84% | -548.88% | -582.88% | -1,580.02% | -897.71% | -1,842.27% | -39.11% | 4.33% | 11.65% | -71.47% | -60.63% | -27.04% | -90.30% |
| Operating Income | -8.23M | -10.12M | -14.73M | -10.03M | -9.28M | -7.59M | -7.13M | -5.96M | -3.65M | -5.32M | 556.50K | 1.56M | -10.74M | -9.99M | -5.33M | -190.78K |
| Operating Income Ratio | -283.90% | -345.21% | -612.67% | -625.85% | -552.18% | -586.09% | -939.70% | -1,004.45% | -1,154.93% | -42.52% | 3.25% | 10.00% | -69.78% | -62.87% | -31.82% | -90.30% |
| Total Other Income/Expenses | 1.43M | 430.42K | 1.66M | 731.71K | 984.93K | 894.53K | 4.92M | 2.58M | 2.18M | 47.81K | -984.55K | -142.86K | -41.87K | -442.94K | -725.71K | 190.78K |
| Income Before Tax | -6.80M | -9.74M | -13.07M | -9.29M | -8.30M | -6.70M | -2.20M | -3.37M | -1.47M | -5.98M | -428.05K | 1.42M | -10.82M | -10.45M | -6.07M | 0.00 |
| Income Before Tax Ratio | -234.42% | -332.23% | -543.73% | -580.18% | -493.59% | -517.03% | -290.41% | -568.52% | -464.06% | -47.75% | -2.50% | 9.09% | -70.33% | -65.80% | -36.26% | 0.00% |
| Income Tax Expense | 0.00 | -364.37K | -148.60K | 31.32K | 10.31K | -1.01M | -66.69K | 238.07K | -69.44M | 127.39K | 229.83K | 68.00K | 63.11K | 64.23K | 9.71K | 190.78K |
| Net Income | -6.80M | -9.37M | -12.92M | -9.33M | -8.31M | -5.69M | -2.14M | -3.61M | 65.79M | -5.98M | -428.05K | 1.35M | -10.88M | -10.51M | -6.08M | -190.78K |
| Net Income Ratio | -234.42% | -319.79% | -537.54% | -582.13% | -494.21% | -439.36% | -281.61% | -608.67% | 20,837.76% | -47.75% | -2.50% | 8.65% | -70.74% | -66.20% | -36.32% | -90.30% |
| EPS | -0.24 | -0.33 | -0.46 | -0.34 | -0.31 | -0.21 | -0.07 | -0.10 | 1.91 | -0.18 | -0.01 | 0.04 | -0.45 | -0.48 | -0.42 | -0.04 |
| EPS Diluted | -0.24 | -0.33 | -0.46 | -0.34 | -0.31 | -0.21 | -0.07 | -0.10 | 1.91 | -0.18 | -0.01 | 0.04 | -0.45 | -0.48 | -0.37 | -0.04 |
| Weighted Avg Shares Out | 28.80M | 28.36M | 27.84M | 27.47M | 27.00M | 27.67M | 28.92M | 36.54M | 34.37M | 34.10M | 32.80M | 33.74M | 24.42M | 22.13M | 14.39M | 5.00M |
| Weighted Avg Shares Out (Dil) | 28.80M | 28.36M | 27.84M | 27.47M | 27.00M | 27.67M | 28.92M | 36.54M | 34.37M | 34.10M | 32.80M | 34.23M | 24.42M | 22.13M | 16.32M | 5.00M |
Dyadic to Present at Industry and Investor Events in October
JUPITER, Fla., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs...
Dyadic and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells
JUPITER, Fla. and PARIS, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI) and bYoRNA SAS ("bYoRNA") today announced that they entered into a development and commercialization agreement to work on disruptive bioproduction technologies that will help...
Dyadic Announces Development and License Agreement to Commercialize Animal-Free Alternative Proteins Using Dapibus™
JUPITER, Fla., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and...
Dyadic to Present at BioProcess International
JUPITER, Fla., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs...
Dyadic International, Inc. (DYAI) Q2 2023 Earnings Call Transcript
Dyadic International, Inc. (NASDAQ:DYAI ) Q2 2023 Earnings Conference Call August 9, 2023 5:00 PM ET Company Participants Ping Rawson - Chief Financial Officer Mark Emalfarb - President and Chief Executive Officer Joseph Hazelton - Chief Business Officer Conference Call...
Dyadic Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
JUPITER, Fla., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to develop and produce biopharmaceuticals and alternative proteins for human...
Dyadic Announces Continued Progress Towards Commercialization of Animal-Free Recombinant Serum Albumin
JUPITER, Fla., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to develop and manufacture biopharmaceuticals and alternative proteins for food,...
Dyadic to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023
JUPITER, Fla., July 26, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and...
Dyadic Provides Phase 1 Clinical Trial Update for its Recombinant Protein RBD Vaccine Candidate
JUPITER, Fla., July 24, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein...
Dyadic International, Inc. (DYAI) Q1 2023 Earnings Call Transcript
Dyadic International, Inc. (NASDAQ:DYAI ) Q1 2023 Earnings Conference Call May 10, 2023 5:00 PM ET Company Participants Ping Rawson - Chief Financial Officer Mark Emalfarb - President and Chief Executive Officer Joseph Hazelton - Chief Business Officer Conference Call...
Source: https://incomestatements.info
Category: Stock Reports